AOD-9604 vs Semaglutide
Compare AOD-9604, Semaglutide: half-life, time to Cmax, dosing interval, published dose ranges and titration — citation-backed, research use only.
| AOD-9604View AOD-9604 → | SemaglutideOzempic, Wegovy, RybelsusView Semaglutide → | |
|---|---|---|
| Class | Metabolic | GLP-1 |
| Route | Subcutaneous | Subcutaneous |
| Plasma half-life | 1 h | ~6.9 days (165 h) |
| Time to Cmax | ~30 min | 24 h |
| Typical interval | Once daily | Once weekly |
| Published dose range | 0.3–0.5 mg | 0.25–2.4 mg |
| Titration ladder | No preset ladder | 0.25 → 0.5 → 1 → 1.7 → 2.4 mg |
| Summary | Hexadecapeptide fragment (177-191) of human growth hormone. Studied for lipolytic effects. | Long-acting GLP-1 receptor agonist. Once-weekly subcutaneous. Titration over 16 weeks reduces GI side effects. |
Source references
AOD-9604
- Heffernan M et al., Endocrinology 142:5182 (2001)
Semaglutide
- FDA Wegovy USPI — half-life ~1 week (165 h) (2024)
- STEP 1 trial — NEJM 384:989 (titration schedule) (2021)
- Hall S et al., Clin Pharmacokinet 57:1571 (Cmax ~24 h SC) (2018)
For research use only. Not for human consumption. This tracker visualises only the doses you have logged or scheduled — it does not recommend dose sizes, does not suggest what to take, and is not pharmacokinetically calibrated. It is not medical advice and does not diagnose, treat, cure, or prevent any condition. Consult a licensed clinician before making any medical decision.